Your browser doesn't support javascript.
loading
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
Friedlander, Michael; Mileshkin, Linda; Lombard, Janine; Frentzas, Sophia; Gao, Bo; Wilson, Michelle; Meniawy, Tarek; Baron-Hay, Sally; Briscoe, Karen; McCarthy, Nicole; Fountzilas, Christos; Cervantes, Andres; Ge, Ruimin; Wu, John; Spira, Alexander.
Afiliação
  • Friedlander M; University of New South Wales Clinical School and Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia. michael.friedlander@health.nsw.gov.au.
  • Mileshkin L; Department of Medical Oncology, Peter MacCallum Cancer Centre, and the Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Parkville, VIC, Australia.
  • Lombard J; Medical Oncology, Calvary Mater Newcastle, NSW, Australia.
  • Frentzas S; Department of Medical Oncology, Monash Health and Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, VIC, Australia.
  • Gao B; Medical Oncology Department, Blacktown Hospital, Sydney, NSW, Australia.
  • Wilson M; Department of Cancer and Blood, Auckland City Hospital, Auckland, New Zealand.
  • Meniawy T; Department of Medical Oncology, Linear Clinical Research and University of Western Australia, Nedlands, WA, Australia.
  • Baron-Hay S; Department of Medical Oncology, Royal North Shore Hospital, St Leonards, NSW, Australia.
  • Briscoe K; GenesisCare, Melbourne, VIC, Australia.
  • McCarthy N; Department of Medical Oncology, Mid North Coast Cancer Institute, Coffs Harbour, NSW, Australia.
  • Fountzilas C; Department of Medical Oncology, Icon Cancer Centre Wesley, Auchenflower, QLD, Australia.
  • Cervantes A; Department of Medicine/Division of GI Medicine and Early Phase Clinical Trial Program, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Ge R; Department of Medical Oncology, Hospital Clínico Universitario, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Wu J; Instituto de Salud Carlos III, CIBERONC, Madrid, Spain.
  • Spira A; Department of Clinical Development, BeiGene (Beijing) Co., Ltd., Beijing, China.
Br J Cancer ; 129(5): 797-810, 2023 09.
Article em En | MEDLINE | ID: mdl-37474720
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína BRCA1 / Neoplasias de Mama Triplo Negativas Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína BRCA1 / Neoplasias de Mama Triplo Negativas Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Br J Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Austrália